Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease
Author:
- 1 June 2014
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 28 (3) , 437-449
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research
- Addenbrooke's Charitable Trust, Cambridge University Hospitals
- Evelyn Trust
This publication has 100 references indexed in Scilit:
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociNature Genetics, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- OX40 is required for regulatory T cell–mediated control of colitisJournal of Experimental Medicine, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- A protective function for interleukin 17A in T cell–mediated intestinal inflammationNature Immunology, 2009
- Regulation of inflammatory responses by IL-17FJournal of Experimental Medicine, 2008
- Interleukin-23 drives innate and T cell–mediated intestinal inflammationJournal of Experimental Medicine, 2006